首页> 美国卫生研究院文献>The Scientific World Journal >Evaluation of Renal Gene Expression of Protein Kinase C (PKC) Isoforms in Diabetic and Nondiabetic Proliferative Glomerular Diseases
【2h】

Evaluation of Renal Gene Expression of Protein Kinase C (PKC) Isoforms in Diabetic and Nondiabetic Proliferative Glomerular Diseases

机译:糖尿病和非糖尿病性增生性肾小球疾病中蛋白激酶C(PKC)亚型的肾脏基因表达的评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The protein kinase C (PKC) family consists of 13 members categorized as conventional or novel depending on whether diacylglycerol, calcium, or phosphatidylserine is required for activation. High glucose leads to activation of different forms of PKC across tissue types, thus determining the kind of diabetes-induced organ damage. PKC β was reported to have a positive role in B-lymphocyte activity through activation of NF-κB, leading to various immune disorders. We examined renal expression of two PKC isoforms α and β in renal biopsies of patients with diabetic nephropathy, lupus nephritis (LN) (Class 3-4), and mesangioproliferative glomerulonephritis (MPGN) to explore the role of each isoform in different glomerular diseases. PKC α and β gene expression was studied by quantitative real-time reverse transcription-PCR in 20 patients with type 2 diabetes and proteinuria (serum creatinine 2.04 ± 0.85 mg/dl, 24-h urinary protein 3.61 ± 1.75 g, eGFR 37.85 ± 17.89 ml/min/1.73 m2), 20 patients with proliferative LN (serum creatinine 1.67 ± 1.50 mg/dl, 24-h urinary protein 4.46 ± 5.01 g, eGFR 69.62 ± 40.93 ml/min/1.73 m2), and 20 patients with MPGN (serum creatinine 3.32 ± 2.79 mg/dl, 24-h urinary protein 4.65 ± 4.11 g, eGFR 32.62 ± 29.56 ml/min/1.73 m2). Normal tissues from the normal pole of four kidneys removed because of renal tumor served as controls. PKC α gene expression was significantly increased in diabetic kidneys compared to LN and MPGN (316.95 ± 152.94 µg/ml vs. 185.97 ± 32.13 and 195.46 ± 46.45 µg/ml, p < 0.05). PKC β gene expression was significantly increased in the LN and MPGN groups compared to the diabetic nephropathy group (41.01 ± 14.03 and 39.93 ± 16.41 µg/ml, respectively, vs. 18.20 ± 4.91 µg/ml, p < 0.05). Significant correlation was noted between the PKC α gene concentrations and proteinuria in diabetic patients. Renal expression of PKC α and β genes in control tissues were significantly lower compared to diabetic kidneys, LN, and MPGN groups (32.31 ± 0.36 and 4.67 ± 2.41 µg/ml, respectively, p < 0.001). The study revealed enhanced renal gene expression of both PKC isoforms α and β in diabetic kidney tissues, LN, and MPGN, but in different patterns. PKC α gene expression was significantly increased in diabetic patients with chronic kidney disease. The increased expression of the PKC β gene in LN and MPGN highlights its role in regulation of the immune system. This may represent potential therapeutic targets for prevention of progressive kidney injury in diabetic and proliferative glomerular diseases.
机译:蛋白激酶C(PKC)家族由13个成员组成,这些成员根据激活是否需要二酰基甘油,钙或磷脂酰丝氨酸而分为常规的或新颖的。高血糖会导致不同组织类型的PKC活化,从而确定糖尿病引起的器官损伤的类型。据报道,PKCβ通过激活NF-κB在B淋巴细胞活性中具有积极作用,从而导致各种免疫疾病。我们在糖尿病性肾病,狼疮性肾炎(LN)(3-4级)和中血管增生性肾小球性肾炎(MPGN)患者的肾脏活检中检查了两种PKC亚型α和β的肾脏表达,以探讨每种亚型在不同肾小球疾病中的作用。通过定量实时逆转录PCR技术研究了20例2型糖尿病和蛋白尿(血清肌酐2.04±0.85 mg / dl,24小时尿蛋白3.61±1.75 g,eGFR 37.85±17.89)的PKCα和β基因表达ml / min / 1.73 m 2 ),20例增殖性LN患者(血清肌酐1.67±1.50 mg / dl,24小时尿蛋白4.46±5.01 g,eGFR 69.62±40.93 ml / min / 1.73 m 2 )和20例MPGN患者(血清肌酐3.32±2.79 mg / dl,24小时尿蛋白4.65±4.11 g,eGFR 32.62±29.56 ml / min / 1.73 m 2 )。将由于肾脏肿瘤而从四个肾脏的正常极移出的正常组织作为对照。与LN和MPGN相比,糖尿病肾中的PKCα基因表达显着增加(316.95±152.94 µg / ml与185.97±32.13和195.46±46.45 µg / ml,p <0.05)。与糖尿病肾病组相比,LN和MPGN组的PKCβ基因表达显着增加(分别为41.01±14.03和39.93±16.41 µg / ml,而18.20±4.91 µg / ml,p <0.05)。糖尿病患者的PKCα基因浓度与蛋白尿之间存在显着相关性。与糖尿病肾,LN和MPGN组相比,对照组织中PKCα和β基因的肾脏表达显着降低(分别为32.31±0.36和4.67±2.41 µg / ml,p <0.001)。该研究揭示了糖尿病肾组织,LN和MPGN中PKC亚型α和β的肾脏基因表达增强,但模式不同。在患有慢性肾脏病的糖尿病患者中,PKCα基因表达显着增加。 PKCβ基因在LN和MPGN中的表达增加,突显了其在调节免疫系统中的作用。这可能代表了预防糖尿病和增生性肾小球疾病进行性肾脏损伤的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号